Skip to content Skip to footer
Subscribe Now
PharmaShots Interview Pierre Fabre’ Roberta Valenti Shares Insights on Nerlynx (neratinib) for the Treatment of HER2 Early Breast Cancer
VIEWPOINTS

PharmaShots Interview: Pierre Fabre’ Roberta Valenti Shares Insights on Nerlynx (neratinib) for the Treatment of HER2 Early Breast Cancer

In an interview with PharmaShots, Roberta Valenti, Global Medical Director at Pierre Fabre shared her views on Nerlynx (neratinib) in P-II (CONTROL) study & showed improved tolerability with all the investigated diarrhoea prophylaxis strategies, presented at SABCS 2021 Shots: The P-II (CONTROL) study evaluates 6 preventive antidiarrheal prophylaxis options with loperamide for the prevention of neratinib-associated diarrhoea. Patients will receive neratinib (240 mg/day) for 1yr.…
April 27, 2022

Read more

PharmaShots Interview ViiV Healthcare’s Kimberly Smith Shares Insights on Apretude for the Prevention of HIV
VIEWPOINTS

PharmaShots Interview: ViiV Healthcare’s Kimberly Smith Shares Insights on Apretude for the Prevention of HIV

In an interview with PharmaShots, Kimberly Smith, Senior Vice President, Head of Research & Development at ViiV Healthcare shared her views on the US FDA’s approval of the first long-acting injectable option of Apretude for the prevention of HIV The approval is based on the P-IIb/III (HPTN 083/084) trial to evaluate cabotegravir (q8w) vs FTC/TDF (200/300 mg) in 7,700+ patients who…
April 26, 2022

Read more

PharmaShots Interview Janssen’s Soumya D. Chakravarty Shares Insights on Tremfya (guselkumab) for the Treatment of Active Psoriatic Arthritis
VIEWPOINTS

PharmaShots Interview: Janssen’s Soumya D. Chakravarty Shares Insights on Tremfya (guselkumab) for the Treatment of Active Psoriatic Arthritis

In an interview with PharmaShots, Soumya D. Chakravarty, Senior Director, Strategic Lead, Rheumatology Therapeutic Area at Janssen shared his views on the data of Tremfya in the P-IIIb (COSMOS) trial for the treatment of active psoriatic arthritis, published in the Annals of the Rheumatic Diseases The P-IIIb (COSMOS) trial evaluates Tremfya (100mg) vs PBO in a ratio (2:1) in 285 patients with active PsA…
April 25, 2022

Read more

PharmaShots Interview Sanofi’s Chris Soria Shares Insights on Amcenestrant for the Treatment of Breast Cancer
VIEWPOINTS

PharmaShots Interview: Sanofi’s Chris Soria Shares Insights on Amcenestrant for the Treatment of Breast Cancer

In an interview with PharmaShots, Chris Soria, Global Project Head of Amcenestrant at Sanofi shared his views on the updated data of Amcenestrant in the P-I/II (AMEERA-1) study for ER+/HER2−metastatic breast cancer, presented at SABCS 2021 Shots: The P-I/II (AMEERA-1) study evaluated amcenestrant as monothx. & in combination with targeted therapies in postmenopausal women with ER+/HER2- MBC In a pooled analysis of 35…
April 20, 2022

Read more

PharmaShots Interview Jon Heinrichs of Sanofi Pasteur & Tonya Villafana of AstraZeneca Shares Insights on Nirsevimab in Healthy Infants Born at Term or Late Preterm
VIEWPOINTS

PharmaShots Interview: Jon Heinrichs of Sanofi Pasteur & Tonya Villafana of AstraZeneca Shares Insights on Nirsevimab in Healthy Infants Born at Term or Late Preterm

In an interview with PharmaShots, Jon Heinrichs, Associate, Vice President, and the Head of Innovation and Emerging Sciences at Sanofi Pasteur & Tonya Villafana, Vice President, Global Franchise Head, Infection at AstraZeneca share their views on the data of Nirsevimab in P-III (MELODY) trial to protect infants against Respiratory Syncytial Virus Shots: The P-III (MELODY) trial evaluates nirsevimab (50/100mg, IM) vs…
April 19, 2022

Read more

PharmaShots Interview Reproductive Solutions’ Diana Peninger Shares Insights on ProteX, a Solution for Male Infertility
VIEWPOINTS

PharmaShots Interview: Reproductive Solutions’ Diana Peninger Shares Insights on ProteX, a Solution for Male Infertility

In an interview with PharmaShots, Diana Peninger, President and CEO at Reproductive Solutions shares her views on the ProteX sperm collection solution, offering a new hope for infertile couples. Shots: Reproductive Solutions (RSI) reported the availability of a patented, FDA-listed semen collection container that improves specimen quality for in vitro fertilization and other assisted reproductive technologies The ProteX container…
April 18, 2022

Read more

Disease of the Month: Chagas Disease (American Trypanosomiasis)
INSIGHTS+

Disease of the Month: Chagas Disease (American Trypanosomiasis)

INTRODUCTION Chagas disease also known by the name American trypanosomiasis, is a zoonotic infection, caused by protozoan flagellate Trypanosoma cruzi (kissing bugs). It is potentially a life-threatening infection transmitted to people and animals from the feces of blood-sucking bugs which belong to the subfamily of Triatominae2. Among all the vectors, Rhodnius proxilus, Panstrongylus megistus, and…
April 14, 2022

Read more

PharmaShots Interview Fountain Therapeutics’ William Greene Shares Insights on the $15M Series A-2 Financing
VIEWPOINTS

PharmaShots Interview: Fountain Therapeutics’ William Greene Shares Insights on the $15M Series A-2 Financing

In an interview with PharmaShots, William Greene, CEO at Fountain Therapeutics shares his views on the closing of $15M Series A-2 financing & how it supports the drug discovery platform and pipeline Shots: The company closes $15M series A-2 financing bringing its total Series A funding to $26M which was led by Eli Lilly, Alexandria Venture Investments, and R42 Group as new…
April 13, 2022

Read more

Load more